A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

BACKGROUND & AIMS: Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1–F3 fibrosis. The primary objective of the BALANCED Cohort C was to assess the safety and tolerability of efruxifermin in patients with compensated NASH cirrhosis. METHODS: Pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Stephen A., Ruane, Peter J., Freilich, Bradley, Neff, Guy, Patil, Rashmee, Behling, Cynthia, Hu, Chen, Shringarpure, Reshma, de Temple, Brittany, Fong, Erica, Tillman, Erik J., Rolph, Timothy, Cheng, Andrew, Yale, Kitty
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832280/
https://www.ncbi.nlm.nih.gov/pubmed/36644237
http://dx.doi.org/10.1016/j.jhepr.2022.100563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832280/
https://www.ncbi.nlm.nih.gov/pubmed/36644237
http://dx.doi.org/10.1016/j.jhepr.2022.100563

Ejemplares similares